Trials / No Longer Available
No Longer AvailableNCT03134131
Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Jazz Pharmaceuticals · Industry
- Sex
- All
- Age
- 3 Years
- Healthy volunteers
- —
Summary
The objective of this expanded access program is to provide ONC201 to eligible patients with previously-treated glioma that exhibits the H3 K27M mutation and/or that is located in the midline region of the brain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ONC201 | ONC201 is an oral, small molecule selective antagonist of DRD2 that induces tumor cell death. |
Timeline
- First posted
- 2017-04-28
- Last updated
- 2022-03-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03134131. Inclusion in this directory is not an endorsement.